PE20142374A1 - Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico - Google Patents

Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico

Info

Publication number
PE20142374A1
PE20142374A1 PE2014001111A PE2014001111A PE20142374A1 PE 20142374 A1 PE20142374 A1 PE 20142374A1 PE 2014001111 A PE2014001111 A PE 2014001111A PE 2014001111 A PE2014001111 A PE 2014001111A PE 20142374 A1 PE20142374 A1 PE 20142374A1
Authority
PE
Peru
Prior art keywords
ethyl
benzyloxy
imino
benzyl
methyl
Prior art date
Application number
PE2014001111A
Other languages
English (en)
Inventor
Lech Ciszewski
La Cruz Marilyn De
Piotr H Karpinski
Michael Mutz
Christian Riegert
Caspar Vogel
Ricardo Schneeberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20142374A1 publication Critical patent/PE20142374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

REFERIDA A UNA SAL HEMIFUMARATO DE ACIDO 1-(4-{1-[(E)-4-CICLOHEXIL-3-TRIFIUORO-METIL-BENCILOXI-IMINO]-ETIL}-2-ETIL-BENCIL)-AZETIDIN-3-CARBOXILICO Y A SU FORMA CRISTALINA A QUE PRESENTA UN PATRON DE DIFRACCION DE POLVO DE RAYOS X CON PICOS A 2 THETA: 6,9�, 10,1�, 10,6�, 12,1�, 15,7�, 16,2�, 17,5�, 18,1�, 20,4�, 20,7�, 22,1�, 24,0� Y 27,3�
PE2014001111A 2008-12-18 2009-12-16 Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico PE20142374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
PE20142374A1 true PE20142374A1 (es) 2015-01-30

Family

ID=42236293

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001226A PE20120336A1 (es) 2008-12-18 2009-12-16 Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-triflouro-metil-benciloxi-imino)-etil)-2-etil-bencil]-azetidin-3-carboxilico
PE2014001111A PE20142374A1 (es) 2008-12-18 2009-12-16 Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001226A PE20120336A1 (es) 2008-12-18 2009-12-16 Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-triflouro-metil-benciloxi-imino)-etil)-2-etil-bencil]-azetidin-3-carboxilico

Country Status (36)

Country Link
US (6) US20120115840A1 (es)
EP (2) EP2676953B1 (es)
JP (1) JP5627597B2 (es)
KR (5) KR20170062554A (es)
CN (2) CN104803902A (es)
AR (3) AR074694A1 (es)
AU (1) AU2009335924B2 (es)
BR (1) BRPI0923176B8 (es)
CA (2) CA2747437C (es)
CL (1) CL2011001490A1 (es)
CO (1) CO6390104A2 (es)
CY (2) CY1114662T1 (es)
DK (2) DK2379497T3 (es)
EC (1) ECSP11011210A (es)
ES (2) ES2436197T3 (es)
HK (1) HK1159631A1 (es)
HR (2) HRP20131106T1 (es)
HU (1) HUE034819T2 (es)
IL (3) IL294514A (es)
JO (1) JO2894B1 (es)
LT (1) LT2676953T (es)
MA (1) MA32961B1 (es)
MX (1) MX2011006609A (es)
MY (1) MY152669A (es)
NZ (1) NZ593061A (es)
PE (2) PE20120336A1 (es)
PL (2) PL2676953T3 (es)
PT (2) PT2379497E (es)
RS (2) RS53041B (es)
RU (1) RU2518114C3 (es)
SG (1) SG171785A1 (es)
SI (2) SI2379497T1 (es)
TW (2) TWI500603B (es)
UY (1) UY32330A (es)
WO (1) WO2010080409A1 (es)
ZA (1) ZA201103709B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2661261T (pt) * 2011-01-07 2019-10-25 Novartis Ag Formulações imunossupressoras.
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
PT3129006T (pt) 2014-04-10 2021-04-09 Novartis Ag Formulação imunossupressora
EP4074312A1 (en) * 2014-04-10 2022-10-19 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3400211A1 (en) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CN111405897A (zh) 2017-09-27 2020-07-10 雷迪博士实验室有限公司 辛波莫德、其盐及其固态形式的制备方法
WO2019064185A1 (en) * 2017-09-27 2019-04-04 Novartis Ag PARENTERAL FORMULATION COMPRISING SITOMOD
RU2020114750A (ru) 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
CN111132677A (zh) * 2017-09-29 2020-05-08 诺华股份有限公司 西尼莫德的给药方案
EP3743405B1 (en) * 2018-01-22 2023-11-15 Teva Pharmaceuticals International GmbH Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
WO2020174408A1 (en) * 2019-02-27 2020-09-03 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
EP3972954A1 (en) 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US20230212115A1 (en) * 2020-05-29 2023-07-06 Cipla Limited Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forme thereof
EP4217341A1 (en) 2020-09-25 2023-08-02 Synthon B.V. Siponimod salts and cocrystals
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (zh) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 一种羧酸类化合物半富马酸盐的晶型及其制备方法
US20240150282A1 (en) 2021-03-26 2024-05-09 Olon S.P.A. Novel crystalline compound of siponimod hemifumarate
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
DE69203164T2 (de) * 1991-06-04 1995-11-02 Fujisawa Pharmaceutical Co Vorbeugende/therapeutische Zusammensetzung für die Pleuropneumonie des Schweins.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
EP0716863B1 (en) * 1993-06-08 2002-05-08 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO1997037970A1 (fr) * 1996-04-04 1997-10-16 Sankyo Company, Limited Derives d'acide phenylalkylcarboxylique
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
CA2433181C (en) * 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20030216376A1 (en) * 2002-03-20 2003-11-20 Revital Lifshitz-Liron Crystalline forms of quetiapine hemifumarate
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (en) 2003-06-13 2004-12-23 Stephen Dichiera Adjustable bed support and bed
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
JP2008521827A (ja) * 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストの投与レジメン
JP2009503108A (ja) * 2005-08-04 2009-01-29 ノバルティス アクチエンゲゼルシャフト ビルダグリプチン塩
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008061622A1 (en) * 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate

Also Published As

Publication number Publication date
JO2894B1 (en) 2015-09-15
TW201035048A (en) 2010-10-01
CA2747437C (en) 2018-08-21
PT2676953T (pt) 2017-06-29
BRPI0923176A8 (pt) 2017-09-12
KR20160129915A (ko) 2016-11-09
PL2676953T3 (pl) 2017-09-29
TWI500603B (zh) 2015-09-21
PT2379497E (pt) 2013-11-29
RU2518114C3 (ru) 2021-11-24
EP2379497B1 (en) 2013-08-21
AR121635A2 (es) 2022-06-22
ES2631203T3 (es) 2017-08-29
IL253845B (en) 2022-08-01
BRPI0923176B1 (pt) 2020-12-01
CY1119037T1 (el) 2018-01-10
KR101885052B1 (ko) 2018-08-02
EP2676953B1 (en) 2017-03-22
US20210323915A1 (en) 2021-10-21
IL213071A0 (en) 2011-07-31
SI2676953T1 (sl) 2017-07-31
RU2518114C2 (ru) 2014-06-10
RU2011129222A (ru) 2013-01-27
HK1159631A1 (es) 2012-08-03
WO2010080409A1 (en) 2010-07-15
JP5627597B2 (ja) 2014-11-19
US20230357142A9 (en) 2023-11-09
AU2009335924A1 (en) 2011-06-30
ECSP11011210A (es) 2011-08-31
TWI591055B (zh) 2017-07-11
KR20170062554A (ko) 2017-06-07
MY152669A (en) 2014-10-31
CY1114662T1 (el) 2016-10-05
US20220402870A1 (en) 2022-12-22
SG171785A1 (en) 2011-07-28
ES2436197T3 (es) 2013-12-27
IL253845A0 (en) 2017-09-28
BRPI0923176B8 (pt) 2021-05-25
LT2676953T (lt) 2017-06-26
CA2951479A1 (en) 2010-07-15
EP2676953A1 (en) 2013-12-25
RS53041B (en) 2014-04-30
HRP20170916T1 (hr) 2017-09-22
NZ593061A (en) 2013-08-30
PL2379497T3 (pl) 2014-01-31
CL2011001490A1 (es) 2012-01-13
AR074694A1 (es) 2011-02-02
TW201509909A (zh) 2015-03-16
KR20180006492A (ko) 2018-01-17
BRPI0923176A2 (pt) 2016-02-16
MA32961B1 (fr) 2012-01-02
US20180118678A1 (en) 2018-05-03
SI2379497T1 (sl) 2013-12-31
CN104803902A (zh) 2015-07-29
AR112227A2 (es) 2019-10-02
CA2747437A1 (en) 2010-07-15
KR20110096584A (ko) 2011-08-30
MX2011006609A (es) 2011-06-30
US20120115840A1 (en) 2012-05-10
DK2676953T3 (en) 2017-07-03
EP2379497A1 (en) 2011-10-26
US20140005162A1 (en) 2014-01-02
ZA201103709B (en) 2012-01-25
KR20160064245A (ko) 2016-06-07
US20150175536A1 (en) 2015-06-25
JP2012512881A (ja) 2012-06-07
RS56110B1 (sr) 2017-10-31
HUE034819T2 (en) 2018-02-28
UY32330A (es) 2010-07-30
CN102256943A (zh) 2011-11-23
HRP20131106T1 (hr) 2013-12-20
PE20120336A1 (es) 2012-04-30
DK2379497T3 (da) 2013-11-25
AU2009335924B2 (en) 2012-11-08
CO6390104A2 (es) 2012-02-29
IL294514A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
PE20142374A1 (es) Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico
PL3800543T3 (pl) Program komputerowy i czytelny dla komputera nośnik zawierający zapisany na nim strumień bitowy do ulepszenia wymiany danych obrazu opierających się na nieliniowości postrzegania luminancji pośród wyświetlaczy o różnych możliwościach
GB2469299B (en) Ensuring consistency between a data cache and a main memory
IL198840A0 (en) Storing log data efficiently while supporting querying to assist in computer network security
BR112012004594A2 (pt) célula hospedeira fúngica filamentosa, e, método para produzir um ácido dicarboxílico
HK1138925A1 (zh) 種監控多數據庫之間數據致性的方法及系統
HK1145833A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ZA201006523B (en) (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-prrrol-3-yl}-acrylamide salts
BRPI0816652A2 (pt) Método para processar uma transação, meio legível por computador, instruções legíveis por máquina, e, aparelho
JP2012214941A5 (es)
BRPI1012260A2 (pt) "aparelhos e métodos para minimizar a interação de fases entre múltiplas soluções de sintonizador"
ZA201105172B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
BRPI1009771A2 (pt) "processo para a preparação de partículas de poliéster com alta carga em uma linha"
ZA201201329B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
DE112006003768A5 (de) Anodenversorgungssystem für einen Brennstoff Zellenstapel sowie Methode zur Reinigung des Anodenversorgungssystems
ZA201004468B (en) Triazolium salts as par1 inhibitors,production thereof,and use as medicaments
BRPI0910364A2 (pt) caixas de varejo e método para a sua produção
BRPI0822509A2 (pt) Fluoroalquilóxi alcanos, processo para sua produção e seus usos
BRPI0811758A2 (pt) Processo e reator para sacarificação de celulose
BR112012001558A2 (pt) alcoxienonas e enaminocetonas e um processo para a sua preparação
BRPI0920702A2 (pt) processo e dispositivo de proteção para produzzir um sinal de defeito indicando uma falha de enrolamento em um transformador
ITTO20050374A1 (it) Fustellato utilizzabile oer realizzare un astuccio piatto trasfromabile in una confezione cilindrica
BRPI0909171A2 (pt) comprimidos aperfeiçoados contendo isomalte e processo para sua produção
BRPI0914774A2 (pt) fibra de celulose e processo para a sua produção
FI8093U1 (fi) Rainanmuodostuskoneen perälaatikko

Legal Events

Date Code Title Description
FC Refusal